SCHEMBL931643

SCHEMBL931643

NC1CCN(c2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBTD1 Q05BQ5 1/20 0.57
L3MBTL3 Q96JM7 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
HTR3E A5X5Y0 2/20 0.50
HTR3B O95264 2/20 0.50
HTR3A P46098 2/20 0.50
HTR3D Q70Z44 2/20 0.50
HTR3C Q8WXA8 2/20 0.50
LMNA P02545 2/20 0.50
ADRB1 P08588 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
VCP P55072 1/20 0.49
NOTUM Q6P988 1/20 0.48
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
GRIN2B Q13224 1/20 0.47
ALOX15 P16050 2/20 0.47
NFKB1 P19838 2/20 0.47
CHRNA7 P36544 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17927700 0.98 MBTD1 (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
Hydrochloric Acid SCHEMBL17748967 0.98 MBTD1 (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL14275856 0.92 L3MBTL1 (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL7845352 0.87 MBTD1 (0.46) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL314421 0.87 NOTUM (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL8386956 0.87 NOTUM (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL21628259 0.87 NOTUM (0.55) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
Hydrochloric Acid SCHEMBL30775623 0.85 NOTUM (0.53) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
Hydrochloric Acid SCHEMBL30775632 0.85 NOTUM (0.53) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B
SCHEMBL4477880 0.84 MBTD1 (0.59) MBTD1L3MBTL3L3MBTL1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768862-A Indole pyrazole compound as well as preparation method and application thereof 郑州大学 2023-09-19 CN claimed
CN-1262548-C Synthesis of benzoxazine monohydrochlorate compound XINYI WANXIANG PHARMACEUTICAL (CN) 2006-07-05 CN claimed
CN-1552699-A Synthesis of benzoxazine monohydrochlorate compound 上海延安万象药业股份有限公司 2004-12-08 CN claimed
EP-0481288-B1 1-Phenylpiperid-4-ylamines and drugs containing them BASF AG (DE) 1995-07-26 EP claimed
WO-2026107349-A1 HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES ANTARES THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
US-12630531-B2 Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient OMIC SMAP INC. (KR) 2026-05-19 US disclosed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CENTAURUS THERAPEUTICS (US) 2026-03-12 US disclosed
CN-120117949-A Method for directly preparing tertiary amine compound from aromatic aldehyde, ketone and secondary amine 湖南大学 2025-06-10 CN disclosed
US-12247019-B2 Inhibitors of dihydroceramide desaturase for treating disease CENTAURUS THERAPEUTICS (US) 2025-03-11 US disclosed
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-25 US disclosed
EP-4370512-A1 CD38 MODULATORS AND METHODS OF USE THEREOF Cytokinetics, Inc. (US) 2024-05-22 EP disclosed
WO-1998008842-A1 CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-05 WO disclosed
WO-1997038665-A2 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-23 WO disclosed
EP-0481288-B1 1-Phenylpiperid-4-ylamines and drugs containing them BASF AG (DE) 1995-07-26 EP disclosed
EP-0481288-B1 1-Phenylpiperid-4-ylamines and drugs containing them BASF AG (DE) 1995-07-26 EP disclosed
US-5317015-A Azacyclic bisphosphonates as anticholesterolemic agents RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1994-05-31 US disclosed
CN-1080918-A Novel aminopropanol derivatives, pharmaceutical compositions containing them and process for preparing them RICHTER GEDEON VEGYESZET (HU) 1994-01-19 CN disclosed
WO-1993025528-A1 NOVEL AMINOPROPANOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME Richter Gedeon Vegyészeti Gyár Rt. (HU) 1993-12-23 WO disclosed
EP-0481288-A2 1-Phenylpiperid-4-ylamines and drugs containing them BASF Aktiengesellschaft (DE) 1992-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CERS2, DEGS1, CERT1 MBTD1 4556/4885L3MBTL3 3290/4885L3MBTL1 1806/4885
US-12247019-B2 Inhibitors of dihydroceramide desaturase for treating disease CERS2, SMPD1, ASAH1 MBTD1 2753/4885L3MBTL3 3644/4885L3MBTL1 1542/4885
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME HAVCR2, HDGF, HCCS MBTD1 1966/4885L3MBTL3 684/4885L3MBTL1 869/4885
US-12630531-B2 Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient EHMT2, EHMT1, HNMT MBTD1 538/4885L3MBTL3 1415/4885L3MBTL1 951/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD MBTD1 4378/4885L3MBTL3 4712/4885L3MBTL1 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.